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Abstract
Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the
alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci
employ to limit complement activation on the bacterial surface. fHbp is a leading vaccine candidate against group B
Neisseria meningitidis. Novel mechanisms that meningococci employ to bind fH could undermine the efficacy of fHbp-based
vaccines. We observed that fHbp deletion mutants of some meningococcal strains showed residual fH binding suggesting
the presence of a second receptor for fH. Ligand overlay immunoblotting using membrane fractions from one such strain
showed that fH bound to a ,17 kD protein, identified by MALDI-TOF analysis as Neisserial surface protein A (NspA), a
meningococcal vaccine candidate whose function has not been defined. Deleting nspA, in the background of fHbp deletion
mutants, abrogated fH binding and mAbs against NspA blocked fH binding, confirming NspA as a fH binding molecule on
intact bacteria. NspA expression levels vary among strains and expression correlated with the level of fH binding; over-
expressing NspA enhanced fH binding to bacteria. Progressive truncation of the heptose (Hep) I chain of lipooligosaccharide
(LOS), or sialylation of lacto-N-neotetraose LOS both increased fH binding to NspA-expressing meningococci, while
expression of capsule reduced fH binding to the strains tested. Similar to fHbp, binding of NspA to fH was human-specific
and occurred through fH domains 6–7. Consistent with its ability to bind fH, deleting NspA increased C3 deposition and
resulted in increased complement-dependent killing. Collectively, these data identify a key complement evasion mechanism
with important implications for ongoing efforts to develop meningococcal vaccines that employ fHbp as one of its
components.
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Introduction
The complement system forms an important arm of innate
immune defenses against Neisseria meningitidis. The presence of
antibody-dependent complement-mediated serum bactericidal
activity predicts protection against invasive disease [1]. Individuals
deficient in components of the alternative or terminal complement
pathways are predisposed to recurrent episodes of meningococcal
infection [2,3,4,5]. In order to survive in its human host, the
meningococcus must evade killing by complement (either direct
lysis by the terminal pathway or complement-dependent opsono-
phagocytosis).
Capsular polysaccharide expression is probably the most
important determinant of meningococcal virulence. Expression
of capsular polysaccharide renders the organism more serum
resistant [6,7], although the molecular basis for capsule-mediated
serum resistance remains undefined. In addition, scavenging host
complement inhibitors by meningococcal membrane proteins
constitutes an important mechanism of subverting complement
attack. Opc has recently been shown to bind to vitronectin [8]
and contribute to serum resistance [9]. Porin (Por) A (PorA) binds
to C4b-binding protein, although binding is best observed under
hypo-osmolar conditions [10]. The molecule that has received
much attention in recent literature is factor H-binding protein
(fHbp; also known as LP2086 [11] or Genome-derived Neisserial
Antigen (GNA) 1870 [12]) that binds to the alternative pathway
inhibitor, factor H (fH) [13,14]. FH acts as a cofactor in the factor
I-mediated cleavage of C3b to the hemolytically inactive
molecule iC3b [15], prevents the association of factor B with
C3b thereby retarding the formation of the alternative pathway
C3 convertase (C3b,Bb) and irreversibly dissociates the alterna-
tive pathway C3 convertase once it is formed [16,17]. Based on
its amino acid sequence, fHbp has been classified into 3 variants
[12], or into 2 subfamilies [11], or more recently, into seven
modular groups [18,19]. Despite the fairly extensive fHbp
sequence variation among strains, representative strains from
each variant family bind to fH [13]. The co-crystal structure of
variant 1 (subfamily B) fHbp with a fragment of fH revealed an
extensive interaction surface of ,2,860 A ˚ 2 [14]. fHbp is currently
being evaluated as protein vaccine candidate against group B
meningococcal disease and has shown promise in Phase III
clinical trials [20].
PLoS Pathogens | www.plospathogens.org 1 July 2010 | Volume 6 | Issue 7 | e1001027In light of the use of fHbp as a vaccine, it is important to define
alternative means of complement evasion that the meningococcus
may employ, in particular scavenging fH. fHbp expression levels
vary markedly across strains. Additional mechanisms to bind to
host fH could undermine the efficacy of fHbp-based vaccines. In
this report we have characterized Neisserial surface protein A
(NspA) as a second acceptor molecule for fH on meningococci and
have established its role in enhancing meningococcal serum
resistance. It is noteworthy that NspA has received attention as a
possible group B meningococcal vaccine; identification of a novel
function for this protein highlights the potential utility of microbial
fH binding molecules as vaccine antigens.
Results
fH binds to fHbp deletion mutants: evidence for an
alternate fH ligand on meningococci
Human fH binds to the meningococcal surface molecule, fHbp
and meningococcal strains, such as H44/76, do not show any
detectable binding of fH by flow cytometry following deletion of
fHbp ([13] and Figure 1A). However, we observed a small but
reproducible, albeit statistically insignificant, binding of fH to
fHbp mutants of some meningococcal strains, such as A2594,
BZ198 and Z2087 by flow cytometry (grey shaded histograms,
Figure 1A) relative to control histograms (Figure 1A, histograms
depicted by broken lines). The amount of fH that bound to the
fHbp deletion mutants of these strains was reduced compared to
their wild-type fHbp expressing parents (histograms depicted by
solid lines, Figure 1A). By contrast, fH binding to the fHbp
deletion mutant of strain H44/76 was below the level of detection
by FACS. These data indicate that some strains of meningococci
may express a second molecule that binds to human fH.
Expression of capsular polysaccharide decreases binding
of fH to fHbp-negative meningococci
Capsule expression in N. meningitidis is subject to phase variation
[21]. Down-regulation of capsule expression occurs during certain
stages of pathogenesis, for example, while traversing the epithelial
barrier [22]. Further, constitutively unencapsulated strains are
commonly found as carriage isolates [23,24,25] and may contribute
to the development of naturally acquired immunity. We have
previously demonstrated that expression of capsule in group B
meningococcal strain H44/76 reduces binding of the complement
regulatory binding protein, C4b-binding protein (C4BP) by about
50% [10]. To determine if the expression of capsular polysaccharide
similarly affects binding of fH to meningococci that lack fHbp
expression, we assessed binding of fH to meningococcal strains in
which capsule production had been abrogated. Deleting capsule from
the fHbp mutants of strains A2594, Z2087, BZ198 and H44/76
revealed that isogenic capsule negative (Cap2) fHbp mutants bound
more fH than their corresponding capsule expressing (Cap+)
counterparts (Figure 1B). Consistent with previous observations
[13,26], deletion of capsule from meningococcal strains that expressed
fHbp did not significantly alter binding of fH to meningococci (data
not shown). While the fHbp mutants of A2594, Z2087 and BZ198
showed a marked increase in fH binding with loss of capsule, only a
minimal increase in fH binding was seen in unencapsulated (Cap2)
fHbp mutant of H44/76, suggesting that the second acceptor for fH
wasexpressed in variableamountsacrossstrains.These data show that
meningococcal strains possess a molecule distinct from fHbp that
serves as a ligand for human fH and that binding of fH to this
molecule is inhibited, to some extent, by capsule expression.
LOS HepI chain length is inversely proportional to fH
binding to fHbp-negative meningococci
LPS length can affect binding of complement inhibitors such as
fH to bacteria [27]. In Neisseria, many of the genes involved in
synthesis of lipooligosaccharide (LOS) are subject to reversible
phase variation and a consequence is that the length of glycan
extensions from HepI varies [28]. Previous work in our laboratory
has shown that altering the length of glycan extensions from HepI
affects binding of the complement inhibitor, C4BP, to gonococci
[29]. To determine if HepI glycan extensions similarly affect
binding of fH to its second ligand on meningococci, we studied the
effects of truncating the glycan residues from HepI on fH binding to
meningococci that lack fHbp. Wildtype strain A2594 expresses a
lacto-N-neotetraose (LNT) extension from HepI and the wildtype
LOS is not modified with sialic acid (LNT LOS sia-/Figure 2A,
blue). Mutants that express a lactose extending from heptose I (lgtA
mutants/L8 LOS/Figure 2A, green) or no saccharides off HepI
(lgtF mutants/unsubstituted HepI LOS/Figure 2A, red) were
created in the background of strains A2594 encapsulated (Cap+)
and A2594 Cap2. As seen in Figure 2B, truncation of the HepI
chain of LOS results in a progressive increase of fH binding to both
Cap+ (left panel) and Cap2 (right panel) meningococci. For a given
LOS phenotype, the Cap+ mutant bound less fH than the
corresponding Cap2 mutant, confirming the observation above
(Figure 1B) that capsule expression negatively impacted fH binding
to the second receptor. In both Cap+ and Cap2 backgrounds, the
trend of increasing fH binding as the length of LOS HepI chain
length decreases was statistically significant (Supplementary Table
S1; p-value for trend test=0.007). The inhibitory influence of
capsule on fH binding to the second meningococcal fH receptor
decreased as HepI LOS chain length decreased. For example, the
differences in fH binding between the Cap+ and Cap2 isogenic
mutants were least apparent when the HepI of LOS was
unsubstituted (red graphs in Figure 2B).
LOS sialylation enhances fH binding to fHbp-negative
meningococci
In N. gonorrhoeae the modification of LNT LOS with sialic acid
dramatically enhances the binding of fH [30], probably by
Author Summary
Neisseria meningitidis is an important cause of bacterial
meningitis and sepsis worldwide. The complement system
is a family of proteins that is critical for innate immune
defenses against this pathogen. In order to successfully
colonize humans and cause disease, the meningococcus
must escape killing by the complement system. In this
study we show that meningococci can use one of its
surface proteins called Neisserial surface protein A (NspA)
to bind to a host complement inhibitory protein called
factor H (fH). NspA is a protein vaccine candidate against
group B meningococcal disease. Binding of fH limits
complement activation on the bacterial surface and
enhances the ability of the meningococcus to resist
complement-dependent killing. Capsular polysaccharide
expression decreases fH binding to NspA, while truncation
of the core glycan chain of lipooligosaccharide increases fH
binding to meningococcal NspA. Loss of NspA results in
enhanced complement activation on the bacterial surface
and increased complement-dependent killing of menin-
gococci. Our findings have disclosed a novel function for
NspA and sheds further light on how this pathogen evades
killing by the complement system.
Neisserial NspA Binds Factor H
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sialylation has not been reported to enhance binding of fH to
meningococci [26,31]. Meningococcal strains that belong to
groups B, C, W-135 and Y can endogenously sialylate their
LNT LOS [32]. Group A strains do not have the capacity to
synthesize 59-cytidinemonophospho-N-acetylneuraminic acid
(CMP-NANA; the donor molecule for sialic acid) and thus cannot
endogenously sialylate their LNT LOS [33,34]. However, they
can scavenge CMP-NANA from the host to sialylate their LNT
LOS. To determine if LOS sialylation affects binding of fH to
fHbp negative meningococci we analyzed fH binding to fHbp2
and Cap2 mutants of group A strains A2594 and Z2087. The use
of group A strains, that cannot endogenously sialylate their LOS,
permitted us to study the effects of increasing amounts of LOS
sialylation on fH binding by varying the amount of CMP-NANA
added to growth media. As seen in Figure 3A, growth of both
strains in CMP-NANA-containing media increased fH binding.
Z2087 Cap2 fHbp2 was then grown in increasing amounts of
CMP-NANA (Figure 3B); fH binding increased as CMP-NANA
concentrations in the growth media were increased and maximal
fH binding was achieved at 5 mg/ml of CMP-NANA. Taken
together, the data presented thus far indicate that binding of fH to
the putative meningococcal second fH receptor is enhanced by
truncation of HepI glycan extensions, sialylation of LNT LOS or
loss of capsule expression.
Identification of NspA as the ligand for fH on fHbp-
negative meningococci
Our studies indicate the presence of a second meningococcal
receptor for human fH, distinct from the previously described
Figure 1. FH binding to fHbp mutants of select N. meningitidis strains and their isogenic capsule deficient mutants. A. fH binding to wild-
type meningococcal strains H44/76, A2594, BZ198 and Z2087 and their fHbp deletion mutants was examined by flow cytometry. Bacteria were
incubated with purified human fH at a concentration of 20 mg/ml and bound fH was detected with polyclonal sheep anti-human fH. Representative
controlswiththewild-typestrainswherefHwasomittedfromthereactionmixtureareshownbythebrokenline.Thex-axisrepresentsfluorescenceona
log10 scale and the y axis is the number of events. Median fluorescence is indicated to the right of each histogram. B. Capsule expression hinders fH
binding to fHbp deletion meningococcal mutants. fHbp deletion mutants of encapsulated strains H44/76, A2594, BZ198 and Z2087 and their isogenic
unencapsulated mutants were incubated with fH at a concentration of 20 mg/ml and bacteria-bound fH was detected with sheep anti-human fH. fH
binding to the encapsulated (Cap+) strains is shown by the shaded histogram and binding to the isogenic unencapsulated (Cap2) mutant is shown by
thesolidline.Representativecontrolswiththewild-typestrainswherefHwasomittedfromthereactionmixtureareshownbythebrokenline.Thex-axis
represents fluorescence on a log10 scale and the y axis the number of events. Median fluorescence is indicated to the right of each histogram.
doi:10.1371/journal.ppat.1001027.g001
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identify the putative second receptor molecule(s) present on fHbp
deletion mutants of N. meningitidis. Membrane proteins prepared
from strains A2594 (binds fH when its fHbp is deleted) and H44/76
(fHbp deletion mutant does not bind detectable amounts of fH by
FACS) were separated on a 4–12% Bis-Tris gel and transferred to
a PVDF membrane. Proteins that bound to fH were identified by
probing the membrane with purified human fH and detecting
bound fH with an anti-fH Ab (Figure 4A, right). An fHbp deletion
mutant of each strain was used as a control. We focused on fH-
reactive bands that were present in A2594 and A2594 fHbp2, but
were either absent or expressed in reduced amounts on H44/76
and H44/76 fHbp2. A prominent fH-binding band of ,17 kD
was apparent in A2594 and A2594 fHbp2. This band was
detected, but with lower intensity, in H44/76 and its fHbp deletion
mutant (Figure 4A, right). This ,17 kD band was not considered
in our previous study where strain H44/76 was employed to
identify fHbp as a fH binding molecule [13] because strain H44/
76 expresses very low levels of this protein; we focused on the more
prominent 29 kD fH-reactive band (fHbp) that was subsequently
validated as the fH ligand on intact bacteria. A Coomassie blue
stained gel showing the total membrane protein profile of each
strain is shown for reference (Figure 4A, left).
To determine the identity of the ,17 kD fH binding molecule,
the region corresponding to the location of the ,17 kD band was
excised from a parallel Coomassie stained gel (indicated by the
asterisk, Coomassie blue stained gel, Figure 4A) and this sample
was subject to in-gel trypsin digestion and MALDI-TOF analysis
followed by peptide mass fingerprinting that was compared with
the Neisseria proteome. The protein band was defined as
Figure 2. Inverse relationship between fH binding to fHbp mutants and length of HepI glycans extensions. A. Schematic depicting the
LOS HepI glycan extensions of the strains used in this study. B. Binding of fH (10 mg/ml) increases as LOS HepI chain length decreases. fH binding to
Cap+ (left panel) and Cap2 (right panel) isogenic mutants of A2594 that express either unsialylated LNT LOS (blue graphs), L8 LOS (green graphs) or
unsubstituted HepI LOS (red graphs) was measured by flow cytometry. Numbers represent median fluorescence of fH binding from a single
representative experiment; color corresponds to the color of the graph. Median fluorescence from three independent experiments was used to
perform a Cuzick’s nonparametric test for trend across ordered groups. The trend of fH binding increasing as HepI chain length decreases is
statistically significant (p-value for trend test p=0.007). The control (dashed histogram) represents a reaction mixture in which fH was excluded;
controls with all mutants yielded similar results and a representative control obtained using the LNT LOS-expressing strain is shown. Axes are as
described for Figure 1A.
doi:10.1371/journal.ppat.1001027.g002
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Fingerprint program for MS data and the MS/MS Ion Search
program for CID data. The peptide ions covered 43% of the total
protein sequence and no other statistically significant matches
were identified. The data suggest that NspA could bind to human
fH.
Figure 3. Sialylation of lacto-N-neotetraose (LNT) LOS enhances binding of fH to fHbp-negative meningococci. A. fH (10 mg/ml)
binding to fHbp deletion mutants of unencapsulated (Cap2) derivatives of strains A2594 (upper panel) and Z2087 (lower panel) grown either with
(sia+) or without (sia2) CMP-NANA (5 mg/ml) added to the growth media was measured by flow cytometry using anti-fH mAb 906. Binding to
sialylated (sia+) strains is shown by the shaded graphs and binding to strains without LOS sialic acid (sia2) by the solid line. Controls (no fH added)
are shown by the dashed line. Numbers represent the median fluorescence of the corresponding histogram. B. fH binding to fHbp2 LNT-bearing
meningococci is dose dependent and saturatable. Z2087 mynB fHbp (Cap2, fHbp2, LNT LOS) was grown in media containing increasing
concentrations of CMP-NANA ranging from 0 to 10 mg/ml. Bacteria were incubated with fH (20 mg/ml) and fH bound to bacteria was detected by flow
cytometry using mAb 906. The average median fluorescence from 3 independent experiments is plotted. Error bars represent standard deviations.
The increases in fH binding were statistically significant (p-value,0.05) for all CMP-NANA concentrations prior to saturation. Controls and axes are as
described in Figure 3A.
doi:10.1371/journal.ppat.1001027.g003
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PLoS Pathogens | www.plospathogens.org 5 July 2010 | Volume 6 | Issue 7 | e1001027One caveat of a Far Western assay is that proteins presented in
non-native conformations may interact in artificial ways with the
ligand, in this case fH, and lead to the detection of ‘‘false positive’’
interactions. The data presented below indicate that NspA is likely
the only additional fH ligand present in these strains and
additional fH reactive bands present on the Far Western blot
(Figure 4A, right) were not analyzed by MALDI-TOF.
Consistent with our previous observations [13], PorA and PorB
also bound to fH on the western blot (Figure 4A, right). Purified
H44/76 PorB3 binds to human fH by ELISA [35], but neither
Figure 4. Identification of NspA as a meningococcal ligand for fH. A. Membrane extracts from strains A2594 and H44/76 and their fHbp
deletion mutants (fHbp2) were separated on a 4–12% Bis-Tris gel, transferred to a PVDF membrane by western blotting and probed with pure
human fH (1 mg/ml). Bound fH was detected with sheep polyclonal anti-human fH. The locations of PorA, PorB and fHbp are indicated. A ,17 kD
molecule that also bound fH is indicated by the arrow. This protein was identified by MALDI-TOF analysis of the co-migrating band on a Coomassie
blue stained gel (indicated by the asterisk) as NspA (see text). B. PorA and PorB are not ligands for fH on intact meningococci. porA and porB3 were
deleted from the background of A2594 Cap2 (right panel) and A2594 Cap2 (left panel), respectively, and fH (10 mg/ml) binding was measured by
flow cytometry using anti-fH mAb 906as the detecting Ab. The shaded graph represents fH binding to the porin deletion mutants and the solid line
represents fH binding to the parent strain. Controls and axes are as described in Figure 1A.
doi:10.1371/journal.ppat.1001027.g004
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PLoS Pathogens | www.plospathogens.org 6 July 2010 | Volume 6 | Issue 7 | e1001027PorB3 nor PorA bind to fH in the context of intact H44/76
bacteria [13,26], and we therefore did not anticipate these
meningococcal porins to serve as ligands for fH on whole bacteria.
The putative surface exposed loops of PorA and PorB show
considerable variation across strains [36,37,38,39] and thus it
remained possible that the porin molecule(s) of A2594, but not
H44/76, served as a ligand for fH. Deleting PorA or PorB3 from
the background of A2594 Cap2 did not diminish fH binding
compared to the respective isogenic Por sufficient parent strains
(right and left graphs of Figure 4B, respectively). This suggests that
neither Por molecule contributed to fH binding to intact A2594
organisms and that the interaction of these proteins with fH in the
Far Western assay is a ‘‘false positive’’.
NspA shares structural similarities with the Neisserial opacity
proteins (Opa) and we sought to determine if Opa might also bind
fH. fH binding to an unencapsulated Z2087 strain that expressed
Opa and its isogenic Opa negative mutant was indistinguishable
(Supplementary data Figure S1), indicating that the Opa proteins
were not ligands for fH.
NspA is a ligand for fH on intact meningococci
Several lines of evidence were used to independently verify that
NspA is a ligand for fH on live, intact meningococci.
i) Deleting NspA abrogates fH binding to intact fHbp-
negative bacteria. To determine the role of NspA in binding to
human fH on intact fHbp-negative meningococci we constructed
nspA deletion mutations in strains BZ198 and A2594. The BZ198
mutants were constructed in a Cap+ strain that expressed either
sialylated LNT LOS (BZ198 is able to endogenously sialylate its
LOS) or L8 LOS. The A2594 mutants were constructed in a Cap2
strain expressing L8 LOS, to maximize binding of fH. All mutations
were constructed in both fHbp+ and fHbp2 backgrounds to
compare the relative contribution of each of these ligands to fH
binding.Theexpression offHbp and NspAwasverified inall strains
by western blot using polyclonal anti-variant 1,2 and 3 fHbp
antiserum and anti-NspA mAb Me-7, respectively (Figure 5A).
Bindingof fHtothenspA deletion mutantsof BZ198andA2594 was
measured by flow cytometry and, as seen in Figure 5B, deleting nspA
uniformly decreased fH binding to all strains. No residual fH
binding to any of the strains was detected when both fHbp and
NspA were deleted. These data, taken together with the direct
binding of fH to NspA observed in the Far Western assay,
confirmed that NspA served as a ligand for fH on intact bacteria. In
addition, these data suggest that the increased fH binding observed
in strains that express truncated (L8) LOS also occurred to NspA
(i.e., no additional fH ligands were exposed).
LNT LOS sialylation enhanced binding of fH to fHbp-negative
meningococci (Figure 3). To determine if the enhanced fH binding
observed in sialylated fHbp-negative meningococci was dependent
on NspA expression, we examined fH binding to an fHbp nspA
double mutant. A2594 Cap2 fHbp2 NspA2 with LNT LOS was
grown in media containing CMP-NANA and, despite LNT LOS
sialylation, there was no increase in fH binding noted by flow
cytometry (data not shown). This upholds that the increased fH
binding seen when the LNT LOS of the group A fHbp deletion
mutants was sialylated (Figure 3A) was not because of fH binding
to LOS sialic acid directly, but that the enhanced binding was
dependent on the concomitant expression of NspA.
ii) Recombinant NspA expressed in E. coli binds to fH and
binding of fH to NspA can be inhibited by an anti-NspA
mAb. Microvesicles prepared from an E. coli strain expressing
recombinant NspA [40] were used to demonstrate direct binding of
fHtoNspAbyELISA(Figure6A).Dose-dependentbindingoffHto
NspA-containing vesicles was observed. In contrast, no binding of
fHwasobserved to vesiclesprepared from an E.coli strainharboring
the plasmid withoutnspAat anyof the fH concentrations tested. The
specificity of fH binding to NspA containing vesicles was further
validated by the ability of the anti-NspA mAb 14C7 to block
binding of fH to vesicles containing NspA (Figure 6A).
Additional evidence that NspA was an acceptor molecule for fH
on the meningococcal surface was provided by the ability of the
anti-NspA mAbs Me-7 and 14C7 to block binding of fH to strain
A2594 Cap2 fHbp2 (Figure 6B). A control mAb (mAb P1.9)
directed against the class I outer membrane protein porin A (PorA)
did not affect fH binding to bacteria. Similar surface binding of the
mAbs used, in the absence of fH, is shown in Figure 6B. Binding of
fH in the absence of any added mAb was similar to that seen with
mAb P1.9 (shaded grey histogram, left panel, Figure 6B).
iii) Increasing NspA expression enhances fH
binding. NspA expression levels vary among meningococcal
strains [41] and it appeared that the amount of fH binding
mirrored expression levels. Consistent with the high levels of fH
binding seen to their fHbp deletion mutants, strains BZ198, A2594
and Z2087 were also high NspA expressers as seen on western blot
analysis of whole bacterial lysates (Figure 7A). Of the strains tested,
H44/76 expressed the lowest levels of NspA, while C2120, W171
and Y2220 all expressed intermediate levels of NspA (Figure 7A).
The results obtained by western blotting were confirmed by flow
cytometry using anti-NspA mAb Me-7 (data not shown).
Expression level of fHbp also varies among meningococcal
strains [12] and fHbp expression in several strains is shown
(Figure 7B). As noted previously, H44/76 is a high fHbp-
expressing strain [13,42] while fHbp expression in Y2220 barely
exceeds the level of detection. The expression of fHbp and NspA
did not vary within a strain in response to the genetic
manipulations described herein (Supplementary Figure S2).
We hypothesized that increasing NspA expression would
enhance fH binding. NspA expression was upregulated by
placing nspA under control of the porA promoter in the
background of wild-type strain Y2220 expressing sialylated
LNT LOS (Cap+/LNT LOS sia+) and Y2220 Cap+/L8 LOS
(Y2220 lgtA::kan). Strain Y2220 was chosen because it expresses
very low levels of fHbp [13]. Thus, the effects of NspA over-
expression on fH binding could be studied with minimal
confounding background fH binding to fHbp. Enhanced NspA
expression by the porA promoter was confirmed by western
blotting (Figure 7C). Increased NspA expression was associated
with increased fH binding (Figure 7D). Again, the strain that
expressed the shorter (L8) LOS bound more fH that the isogenic
mutant with LNT LOS.
Meningococcal strains such as, H44/76, C2120, W171 and
Y2220 express low or intermediate levels of NspA, but do not bind
fH when fHbp is deleted (data with H44/76 shown in Figure 1A
and reference [13], Y2220 shown by solid black histogram in left
panel of Figure 7D; data with C2120 Cap+ and W171 Cap+ are
not shown). The Cap2 mutants of these strains also show minimal
fH binding when they express LNT LOS and when fHbp is deleted
(Supplementary Figure S3). We speculated that further truncation
of LOS in these strains would disclose fH binding. In accordance
with this hypothesis, truncating LOS (lgtF mutants; HepI
unsubstituted) resulted in increased fH binding (Supplementary
Figure S3).
NspA mediates binding of fH to meningococci through
interactions with fH short consensus repeats (SCRs) 6
and/or 7
FHcomprises20shortconsensusrepeat(SCR)domainsarranged
as a single chain [43]. Recently, the cocrystal complex of variant 1
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PLoS Pathogens | www.plospathogens.org 7 July 2010 | Volume 6 | Issue 7 | e1001027Figure 5. Deleting NspA decreases binding of fH to N. meningitidis.A . Expression of fHbp and NspA in BZ198 and A2594 derivatives as
determined by western blotting of whole cell lysates followed by detection with polyclonal anti-fHbp (variant 1,2 and 3) or anti-NspA mAb Me-7 as
indicated. After transfer, proteins migrating above ,50 kD were stained with Coomassie blue and served as a loading control, proteins migrating
between ,20 kD and 40 kD were probed to detect fHbp and proteins migrating below 20 kD were probed to detect NspA. NspA migrates with an
apparent molecular mass of approximately 15 kD when 4–12% Bis-Tris gels are used with MES running buffer. Also, of note, NspA is a heat-modifiable
protein and the second larger anti-NspA-reactive band seen in some lanes is the result if incomplete heat denaturation. B. Strains BZ198 Cap+/LNT
sia+, BZ198 Cap+/L8 LOS and A2594 Cap2/L8 LOS, and their fHbp, nspA or fHbp nspA double mutants were examined for their ability to bind to fH
(20 mg/ml) by flow cytometry. The boxed numbers accompanying each histogram represents the median fluorescence of fH binding of the entire
bacterial population. Controls (shown by the broken lines) represent fluorescence where fH was omitted from the reaction mixture; all strains yielded
similar background binding and, for simplicity, only tracings obtained with the parent strains have been shown. Axes are as described for Figure 1A.
doi:10.1371/journal.ppat.1001027.g005
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fHbp with fH SCR 6 and minor points of contact with SCR 7 [14].
Site-directed mutagenesis studies also localized the fHbp binding
domaininfHtoSCR6 [44].TodeterminethefHSCRsinvolvedin
binding to NspA, we utilized fusion proteins that containcontiguous
fH SCRs fused at their C-terminus to the Fc portion of IgG2a
[44,45]. The Fc fragment served as a ‘tag’ for symmetric detection
of all fusion proteins. The ability of five fH/Fc fusion constructs
(SCR 1–5/Fc, SCR 1–7/Fc, SCR 6–10/Fc, SCR 11–15/Fc and
SCR 16–20/Fc) to bind to meningococcal strain A2594 Cap2 L8
Figure6. RecombinantNspA expressed in E. coli vesicles binds tofH.A. Bindingof fHto microvesiclespreparedfrom anE.coli strainexpressing
recombinant NspA (squares) or to vesicles prepared from the same E. coli strain transformed with the plasmid without the nspA gene (circles) was
measured by ELISA. Binding of fH to vesicles harboring recombinant NspA was blocked by the anti-NspA mAb 14C7 (triangles). Each data point
represents thearithmetic meanoftheOD405nmreadingfrom threeindependentexperiments anderrorbars representthestandard deviation. B. Binding
of fHto A2594Cap2fHbp2 LNT LOS sia2 was measuredin thepresenceofanti-NspAmAb Me-7(purple shaded histogram),anti-NspAmAb14C7 (pink
shaded histogram) or anti-PorA mAb P1.9 (green shaded histogram); all mAbs were used at a concentration of 30 mg/ml and fH binding was detected
using sheep anti-human fH. The control (histogram depicted by a dashed line) represents bacteria incubated with mAb Me-7, followed by addition of
anti-fH and anti-sheep IgG FITC. A control where fH binding was measured in the absence of any added mAb is shown by the grey shaded histogram in
the left panel. Surface binding of each mAb (shading as described above) to A2594 Cap2 fHbp2 LNT LOS sia2 is also shown. The control (dashed line)
represents bacteria incubated with anti-mouse IgG FITC. Median fluorescence is indicated to the right of each histogram.
doi:10.1371/journal.ppat.1001027.g006
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negative mutants, was examined by flow cytometry. Only those fH/
Fc proteins that contained SCRs 6 and 7 (SCR 1–7/Fc, and SCR
6–10/Fc) bound to the NspA expressing strains that lacked fHbp.
This result indicates that like fHbp, NspA binds to SCR 6 and/or 7.
As expected, the SCR 6/7 containing constructs bound to fHbp
expressing strains whilenone of the fHSCR/Fc constructsbound to
mutants lacking both fHbp and NspA.
Factor H-like molecule 1 (FHL-1) comprises fH SCRs 1–7 plus
four unique additional C-terminal amino acids (SFTL) [46]. FHL-
1 also bound to Cap2 fHbp2 A2594 (Supplementary Figure S4),
supporting the conclusion that SCRs 6 and/or 7 play a role in
binding of fH to NspA. This finding is consistent with the NspA
binding site residing in fH SCRs 6 and/or 7.
Together, these data suggest that SCR 6 and/or SCR 7 are
important for binding of fH to NspA. Although less likely, these
Figure 7. fH binding increases with increasing NspA expression. A. Comparison of NspA expression in Cap2 derivatives of strains A2594,
Z2087, H44/76, C2120, W171, Y2220 and BZ198 by western blotting of whole cell lysates followed by detection with anti-NspA mAb Me-7. After
transfer, proteins migrating above 50 kD were stained with Coomassie blue and served as a loading control. B. Comparison of fHbp expression in
strains A2594, Z2087, H44/76, BZ198 and Y2220 by western blotting of whole cell lysates followed by detection with polyclonal anti-variant 1, 2 and 3
fHbp. After transfer, proteins migrating above 40 kD were stained with Coomassie blue and served as a loading control. C. Overexpression of NspA.
The porA promoter was used to increase NspA expression in the backgrounds of Y2220 Cap+/LNT sia+ and Y2220 Cap+/L8 LOS. Bacterial lysates were
subject to western blotting and probed with mAb Me-7. Similar loading of parent and mutant strains was confirmed by Coomassie staining as
described in A. D. Overexpression of NspA enhances fH binding to Y2220 Cap+/LNT sia+ and Y2220 Cap+/L8 LOS. fH binding to the parent strain,
expressing wildtype levels of NspA, is shown by the solid line and binding to the NspA overexpressing isogenic mutant is shown by the grey shaded
histogram. A representative control (no added fH) is shown by the dashed line. Axes are as described in Figure 1A.
doi:10.1371/journal.ppat.1001027.g007
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binding of fH to NspA; studies to precisely localize the NspA
binding region in fH are underway.
Species-specificity of fH binding to N. meningitidis
expressing NspA
N. meningitidis and N. gonorrhoeae are exclusively human pathogens
and the ability of these pathogens to evade complement-mediated
killing in a species-specific fashion may contribute to the narrow
host range of infection [45,47,48]. We have shown previously that
gonococci bind specifically to human C4BP (and in some
instances, chimpanzee C4BP) [48] and human fH [45]. Likewise,
binding of fH to meningococcal fHbp is specific for human fH
[47]. To determine if fH binding to NspA is also species specific we
examined binding of fH from different primate species to N.
meningitidis strain A2594 Cap2 L8 LOS and its isogenic fHbp2,
NspA2 and fHbp2 NspA2 double-negative mutants by Western
blotting (Figure 9A). Strains were incubated with 10% heat-
inactivated human or primate sera to assess direct binding of fH to
bacteria. Heat inactivation destroys heat labile complement
components while leaving fH intact; inactivation of complement
is necessary to prevent detection of complement C3b-mediated
binding of fH to meningococci. Bound fH was detected by
Western blot using polyclonal goat anti- human fH Abs. This Ab
reacts with fH in the primate sera tested (Figure 9B) and as
previously reported, detection of rhesus fH was slightly weaker
[45]. Human fH bound well to all strains that expressed NspA
(Figure 9A), but only weakly to strains that expressed fHbp but
lacked NspA, which is consistent with the fH binding data present
in Figure 6B. Very weak binding of chimpanzee fH to strains
expressing NspA was also noted (Figure 9A). None of the strains
tested bound rhesus fH when incubated with heat-inactivated
rhesus sera (Figure 9A). The fHbp2 NspA2 strain showed barely
detectable binding to human fH, and as expected, did not bind fH
from the other primate species tested (Figure 9A).
NspA expression enhances serum resistance and inhibits
C3 deposition
fH functions to down-regulate the alternative pathway of
complement and bacteria that bind to fH would be expected to
be more resistant to the bactericidal action of serum than those
that do not bind to fH. To determine the relative roles of fHbp and
NspA in serum resistance we examined strains BZ198 Cap+ and
A2594 Cap2 each expressing L8 LOS and their isogenic mutants
that lacked either fHbp or NspA or both for their ability to resist
killing by normal human serum. The concentration of serum used
was determined based on the survival of each parent strain in
serum (Supplementary Figure S5). Loss of NspA expression in
both instances resulted in greater sensitivity to complement-
dependent killing (Figure 10A). It is noteworthy that in these high
NspA-expressing strains, deleting fHbp did not negatively impact
survival. Deleting fHbp from the high fHbp-expressing strain H44/
76, which expresses low levels of NspA, results in decreased serum
resistance [13,42].
Figure 8. Binding of fH/Fc fusion proteins to N. meningitidis fHbp and NspA mutants of A2594. Binding of fH/Fc fusion constructs to
A2594 Cap2 L8 LOS and to its fHbp2, NspA2 and fHbp2 NspA2 double mutants was assessed by flow cytometry using anti-mouse IgG FITC to
disclosure the bound constructs. Strains that expressed either fHbp, NspA or both bound only to fH/Fc fusion constructs that contained SCR 6 and
SCR 7 (SCR 1–7/Fc and SCR 6–10/Fc) of fH. In all graphs, the x-axis represents fluorescence on a log10 scale and the y-axis represents the number of
events. No fusion protein is present in the control tube. One representative experiment of at least three independent experiments is shown.
doi:10.1371/journal.ppat.1001027.g008
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in the factor I-mediated cleavage of C3b [15] and irreversibly
dissociate alternative pathway C3 convertases (decay-accelerating
activity) [16,17]. As expected, mutant strains that lacked NspA
bound more C3 than their NspA-sufficient ‘parent’ strains. The
median fluorescence of C3 binding was ,5-fold more with A2594
Cap2/L8 LOS/NspA2 and ,2.5-fold more with BZ198 Cap+/
L8 LOS compared to their respective isogenic parent strains
(Figure 10B). fH binding (Figure 5B) mirrored survival of bacteria
in serum (Figure 10A) confirming that complement regulation by
NspA occurred at the level of C3 deposition. Similarly, C3
deposition on BZ198 Cap+/LNT sia+/NspA2 was ,1.5-fold
higher than on BZ198 Cap+/LNT sia+ (data not shown).
Complementation of fHbp2 NspA2 double mutants
with NspA restores binding of fH and serum resistance to
meningococci
Meningococcal strain A2594 Cap2 L8 LOS lacking both fHbp
and NspA was complemented, in trans, with NspAA2594 to verify
that the loss in fH binding and concomitant decrease in serum
resistance were not due to secondary changes. As expected,
complementation with NspAA2594 resulted in expression of NspA
as judged by both western blot (data not shown) and flow
cytometry (Figure 11A). Restoration of NspA expression also
restored the ability of fHbp2 NspA2 double mutants to bind fH
(Figure 11A). The ability of the complemented strains to resist
killing by NHS was assessed in a serum bactericidal assay. As
shown above (Figure 10A), A2594 Cap2 L8 LOS lacking both
fHbp and NspA was more sensitive to serum killing than the
parent strain expressing both of these proteins. Complementation
with NspA, alone, restored serum resistance to the mutant strain
lacking both fH ligands, albeit to levels less than that of the parent
strain (Figure 11B). All three strains were completely (100%) killed
in 6.6% NHS (data not shown). Overall, these data indicate that
the lack of fH binding and decreased serum resistance observed in
strains lacking NspA is because of lack of NspA expression and not
the result of secondary changes in these isogenic strains.
Discussion
Several pathogens, including bacteria, fungi, parasites and
viruses bind to fH, which inhibits complement activation on their
Figure 9. Meningococcal NspA binds selectively to human fH. A. Unencapsulated N. meningitidis A2594 expressing L8 LOS and its fHbp2,
NspA2, and fHbp2NspA2 isogenic mutants were incubated with 10% (v/v) heat-inactivated human, chimpanzee and rhesus sera and Western blots
were performed using polyclonal goat anti- human fH. B. Human, chimpanzee and rhesus serum controls at a dilution of 1/200 (v/v) were performed
to ascertain that the goat polyclonal anti-human fH Abs recognized all primate fH tested.
doi:10.1371/journal.ppat.1001027.g009
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a ligand for human fH and has shown that NspA plays a role in
conferring serum resistance to meningococci even in the absence
of expression of the previously characterized fH-binding menin-
gococcal molecule, fHbp. NspA interacts with fH SCRs 6 and/or
7 and like fHbp, preferentially binds to human fH.
It is interesting that all naturally occurring meningococcal
strains reported thus far express both fHbp [12,51] and NspA [52],
suggesting an important role for these proteins in meningococcal
pathogenesis. Prior to this study the function of NspA had not
been defined. The factors that influence fH binding to NspA on
intact bacteria have been characterized in this study, which
Figure 10. NspA expression enhances resistance of meningococci to complement-dependent killing and limits C3 deposition on
bacteria. A. Strains BZ198 Cap+/L8 LOS and A2594 Cap2/L8 LOS and their isogenic mutant derivatives that lacked fHbp, NspA, or both fHbp and
NspA were tested for their ability to resist killing by normal human serum in a serum bactericidal assay. The y-axis represents percent survival. Error
bars indicate standard deviation calculated from 3 independent experiments. In all cases the decreased survival observed in strains that lack NspA
was statistically significant (P,0.02 by a t-test) compared to the parent strain expressing NspA and fHbp B. C3 deposition on strains BZ198 Cap+/L8
LOS and A2594 Cap2/L8 LOS and their isogenic mutants that lacked either fHbp or NspA expression. The BZ198 Cap+ mutants were incubated with
40% NHS while the A2594 Cap2 mutants were incubated with 20% NHS. C3 deposition on bacteria was detected by flow cytometry. Axes are as
described for Figure 1A. Data with the double fHbp2/NspA2 mutant was similar to the NspA2 mutant and has been omitted for ease of
visualization.
doi:10.1371/journal.ppat.1001027.g010
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where NspA-mediated fH binding may assume an important role.
Meningococcal strains that are isolated from the nasopharynx are
often unencapsulated and/or express L8 LOS [53]; high binding
of fH to NspA under these conditions could point to a key role for
NspA in survival of meningococci during nasopharyngeal
colonization (a prerequisite of invasive disease) and in survival of
carrier strains. The positive effects of NspA on bacterial survival
are also seen in encapsulated strains that are high NspA expressers
such as BZ198 when they express L8 LOS (Figure 10A).
Meningococcal isolates often express more than one LOS species
because many of the genes involved in LOS biosynthesis, including
lgtA, are phase variable [28]. Thus, for example, a strain could
express a combination of LNT and L8 LOS species [54,55]. It is
not clear how LOS sialylation, which represents elongation
beyond the LNT structure, enhances fH binding to NspA. One
possibility is that LOS and NspA lie in close proximity and
expression of the unsialylated LNT hinders fH from binding to
NspA; sialylation may alter the conformation of LOS thereby
better exposing the fH binding region of NspA. Another possibility
is that LOS sialic acid itself may act as part of the docking site for
fH. Nevertheless, LOS sialylation is not essential for fH binding to
Figure 11. Complementation of fHbp NspA double mutants with NspA restores fH binding and serum resistance. A. Meningococcal
strain A2594 Cap2/L8 LOS (‘‘parent’’), its fHbp nspA double mutant (fHbp2 NspA2) and its fHbp nspA double mutant complemented with NspA
(fHbp2 NspA2/NspAA2594 comp) were examined for their ability to bind to MAb 14C7 (anti-NspA) and to fH (20 mg/ml) by flow cytometry. The boxed
numbers accompanying each histogram represents the median fluorescence of 14C7 or fH binding to the entire bacterial population. Controls
(shown by the broken lines) represent fluorescence where either mAb 14C7 or fH or was omitted from the reaction mixture. Axes are as described for
Figure 1A. B. Strain A2594 Cap2/L8 LOS (fHbp+ NspA+), its fHbp nspA double mutant (fHbp2 NspA2) and its fHbp nspA double mutant
complemented with NspA (fHbp2 NspA2/NspAA2594 comp) were tested for their ability to resist killing by NHS at concentrations of 3% (left graph)
or 1.5% (right graph) in a serum bactericidal assay. The y-axis represents percent survival. Error bars indicate standard deviation calculated from 3
independent experiments. With 1.5% NHS the decreased survival observed in strains that lack NspA was statistically significant (P,0.02 by a t-test)
compared to the parent strain expressing both NspA and fHbp.
doi:10.1371/journal.ppat.1001027.g011
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also enhances fH binding, but the interaction in that instance
requires the concomitant presence of the gonococcal PorB
molecule [56]. LPS glycan extensions can negatively impact
binding of complement inhibitors to gram-negative bacteria. As an
example, expression of O-antigenic repeats on the LPS of Y.
enterocolitica can block binding of fH to the Ail protein [27].
Neisseriae lack O-antigenic repeats, yet subtle changes in the core
LOS structure can have profound impacts on the binding of
complement inhibitors and serum resistance. The presence of the
proximal Glc off HepI appears to be necessary for optimal C4b-
binding protein (C4BP) binding to porin (Por) B.1B (Por1B)-
expressing gonococci [29].
NspA forms an eight-stranded anti-parallel b-barrel and has
four putative surface exposed loops. A conformational epitope that
includes NspA loop 3 appears to be important for binding of mAbs
Me-7 [57] and 14C7 [40] both of which inhibit fH binding to
NspA on meningococci. It is therefore possible that NspA loop 3
plays a role in the interaction with fH, although steric hindrance
by the surface-bound mAb could account for the ability of the
mAbs to block fH binding. It would be of interest to determine
whether NspA plays a role in fH binding to gonococci because of
the extensive (,95%) sequence similarity between gonococcal and
meningococcal NspA.
Sera from humans may contain naturally-occurring antibodies
that are directed against LNT-expressing LOS and is bactericidal
against group B meningococci [58]. Phase variation of lgtA that
results in L8 LOS expression could subvert killing by these
naturally occurring anti-LNT antibodies. However, truncation of
the HepI chain of LOS could have a negative effect on serum
resistance because of increased accessibility of the 3-phosphoetha-
nolamine (PEA) residue on HepII to C4b [59]; C4b amide-linked
to PEA can lead to downstream complement activation that may
result in bacterial killing. By virtue of enhanced fH binding, high
NspA expressers may be able to dampen excessive complement
activation that is initiated by C4b when LOS is truncated.
It is noteworthy that loss of NspA (leaving fHbp intact) from a
high NspA expressing strain such as A2594 (intermediate fHbp
expression levels) resulted in increased C3 deposition on bacteria,
while loss of fHbp (leaving NspA intact) in that strain did not
enhance C3 deposition (Figure 10B). Strain BZ198 also expresses
high levels of NspA and intermediate levels of fHbp; loss of NspA
resulted in greater enhancement of C3 deposition relative to that
seen when fHbp was deleted (Figure 10B). We have shown
previously that loss of fHbp in high-fHbp expressing strains such as
H44/76 (expresses low levels of NspA) also increases C3
deposition [13,42]. The relative abilities of the two ligands to
regulate C3 deposition on different strains may reflect heteroge-
neity in their expression levels. In addition, variables such as the
amount of capsule expression and the diversity of HepI LOS
extensions could affect the amount of fH binding to NspA and
thereby its ability to regulate C3 deposition. The relative roles of
fHbp and NspA in regulating complement activation in the
context of expression of the different capsular groups and varying
LOS structures is a complex subject that merits further study.
However, it is evident from the current study and from previous
work [13,42,60,61] that both molecules contribute to the ability of
meningococci to resist killing by normal human serum.
fHbp has shown considerable promise as a vaccine candidate
[20]. A vaccine that has fHbp as a component could lead to
selection of meningococcal strains that either do not express, or
express very low amounts of fHbp. Under such circumstances,
high NspA expressers may have a survival advantage. Our data
suggest that including NspA as part of a vaccine strategy that
targets fH-binding proteins on N. meningitidis could, in theory,
overcome this potential obstacle. Indeed, NspA has been
intensively investigated as a vaccine candidate against group B
meningococci [62,63]. Both mAbs against NspA (including Me-7
and 14C7) and polyclonal Abs against NspA (raised by
immunization of mice with meningococcal outer membrane
vesicles that contained native NspA) were bactericidal and
protected against experimental murine infection [52,64]. Although
recombinant NspA expressed in E. coli and purified from inclusion
bodies elicited a good antibody response in humans, these
antibodies were not bactericidal [62]. Recombinant NspA does
not have the same conformation as NspA present in the
meningococcal outer membrane [40,64], suggesting that protec-
tive antibodies may be directed against conformational epitopes.
Another intriguing possibility, in light of our observations that
binding of fH to NspA is restricted to humans, is that human fH
may bind to NspA in the vaccine formulation, which could have
attenuated the antibody response to surface-exposed (and fH
binding) NspA epitopes that otherwise would have elicited a more
productive bactericidal antibody response; this possibility has been
raised previously with regard to the use of fH binding proteins as
vaccines [14,65].
In summary, we have identified an important complement-
evasion function for NspA, an antigen that has been studied for its
potential as a group B meningococcal vaccine candidate. In
addition to the implications for fHbp-based vaccines that are
currently being developed, these findings set the stage for further
studies to characterize NspA-fH interactions that could boost
efforts to develop better meningococcal vaccines.
Materials and Methods
Ethics statement
This study was approved by the Committee for the Protection of
Human Subjects in Research at the University of Massachusetts
Medical School. All subjects who donated blood for this study
provided written informed consent.
Bacterial strains, mutagenesis and bacterial growth
conditions
The relevant phenotypes of the mutants created in N. meningitidis
are listed in Table 1. The characteristics meningococcal strains
used in this study are listed in Supplementary Table S2. Bacteria
were routinely grown on chocolate agar plates supplemented with
IsoVitaleX equivalent at 37uC in an atmosphere enriched with 5%
CO2. GC plates supplemented with IsoVitaleX equivalent were
used for antibiotic selection. Antibiotics where used at the
following concentrations when indicated; 100 mg/ml kanamycin,
7 mg/ml chloramphenicol, 5 mg/ml erythromycin, 50 mg/ml
spectinomycin and 5 mg/ml tetracycline. Escherichia coli strains
(Invitrogen, Carlsbad, CA) were routinely cultured in Luria
Bertani (LB) broth or on LB agar. Antibiotic were used as needed
at the following concentrations: 50 mg/ml kanamycin, 150 mg/ml
ampicillin, 50 mg/ml chloramphenicol, 400 mg/ml erythromycin,
100 mg/ml spectinomycin and 12.5 mg/ml tetracycline.
Construction of lgtA [59], lgtF [59], mynB [56], siaD [59], lst [66]
and fHbp [13] deletion mutants have all been described previously.
Loss of capsule expression was verified by either colony
hybridization or flow cytometry with the appropriate serogroup
specific anti-capsule Ab. Anti-group A mAb JW-A-1 (IgG2a), anti-
group C mAb KS-C-1 (IgG3), anti-group W-135 mAb JW-W1b
(IgG2b) and anti-group Y mAb JW-Y2a (IgM) were provided by
Dr. Dan M. Granoff (Childrens Hospital Oakland research
Institute, Oakland, CA), while anti-group B mAb 2-2-B (IgM)
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and Control (Potters Bar, Hertfordshire, U.K). In addition,
inactivation of siaD (mynB in the case of group A) was verified by
PCR. For serogroups A, C, Y and W-135 the confirmatory PCR
was the amplification of a fragment corresponding to the predicted
size of siaD (or mynB for group A) plus the resistance marker
(,2.5kb for serogroup A using primers NT2 59-ATGATGG-
TAATGGGAAAAGAGT-39 and NT4 59-ATACTTAATAACA-
GAAAATGGCG-39; ,2.9 kb for serogroup C using primers BF
59-AGCGTCAACGAATATGAAACATTAT-39 and CR 59-
CTGCTTAACTTTATTAAGGGCATTG-39 and ,2.8 kb from
serogroups W-135 and Y strains using primers W1618 59-
ATTCCCCATGAACTACATCAGAATA-39 and W2766 59-
TAATGCAAACTCAATTGCAAAACTA-39) coupled with the
absence of a wildtype gene. In serogroup B strains siaD is
inactivated with the 8.9 kb Tn1725 and a lack of amplification of
the wild type siaD, in the presence of a positive control reaction,
was used to demonstrate the lack of the wild type siaD. All Cap2
serogroup B strains were verified by lack of reactivity to the anti-
group B capsule mAb 2-2-B. LOS structure was verified in all
strains and mutants by silver staining of protease K digested
bacterial lysates that had been separated on 12% Bis-Tris gels
(Invitrogen, Carlsbad, CA) using MES buffer (Invitrogen,
Carlsbad, CA) as described previously [67]. In addition insertions
in lgtA or lgtE were verified by PCR.
Mutant derivatives of strain A2594 that lacked PorA or PorB3
expression were constructed using DNA extracted from PorA and
PorB3 deletion mutants in strain H44/76 (porA::kan and porB3::erm,
respectively) that were provided by Dr. Peter Van der Ley
(Laboratory of Vaccine Research, Netherlands Vaccine Institute,
Bilthoven, The Netherlands).
NspA deletion mutants were constructed as follows. A 1.3 kb
fragment of DNA containing nspA was amplified from N.
meningitidis strain A2594 using the primers nspA_F114 (59-
CTCTTTAGGTTCTGCCAAAGGCTTC-39) and nspA_R1122
(59-ATGTTGTGAAGTGGGAAAGTGTTGC-39) and the am-
plicon was cloned into pCR2.1-TOPO (Invitrogen, Carlsbad,
CA). The resulting plasmid was digested with HincII, deleting an
internal 130 bp fragment of nspA, and ligated to a blunt
spectinomycin resistance cassette containing aadA. Linearized
plasmid DNA was used to transform N. meningitidis strains as
previously described [68]. PCR was used to confirm the nspA::spc
genotype and Western blot using anti-NspA mAb Me-7 were
performed to demonstrated loss of NspA.
A derivative of the E. coli-Neisseria shuttle vector pFP12 was
used to complement the nspA::spc mutations in trans. A 1,131 bp
fragment, containing nspA with its native promoter and terminator
was amplified from chromosomal DNA prepared from strain
A2594 using the primers NspA-R1213 StuI 59-GACAGG-
CCTGTTTTGGACATTTCGGATTCCTC-39 and NspA-F102
SphI 59-GACGCATGCCACTATATAAGCGCAAACAAATC-
G-39. The amplified DNA was digested with StuI and SphI and
cloned into identically digested pFP12-GNA1870 [69]. The
resulting construct was then digested with ScaI to allow for the
insertion of a blunt (BsrBI) TetM cassette. The resulting plasmid
construct, pFP12 NspAA2594Tet, was confirmed by DNA sequenc-
ing and by Western blot analysis of E. coli cell lysates using ME-7.
A2594 Cap2 L8 (Cm
R, Kan
R) and its fHbp2 (erm
R) and NspA2
(spc
R) and fHbp2 NspA2 double mutants were transformed with
pFP12 NspAA2594Tet as described above. Tetracycline resistant
transformants were screened by PCR and Western blot with Me-7.
In addition the DNA sequence of the complementing nspA was
verified.
Expression of NspA was up-regulated in some strains that
naturally express low levels of NspA by replacing the nspA
promoter with the promoter of porA. In brief, an approximately
200 bp fragment of DNA containing the promoter region of porA
was amplified by PCR from genomic DNA isolated from group B
strain M986 using the following primers: 59-CTCATCGATGGG-
CAAACACCCGATACG-39 (introducing site ClaI) and 59-
CTCACGCGTGAGGTCTGCGCTTGAATTGTG-39 (intro-
ducing site MluI). This fragment was ligated into a 700 bp region
upstream of nspA amplified by PCR from Z1092 genomic DNA
using primers 59-CATAAGCTTCGTAGCGGTATCCGGCT-
GC-39 and 59-CGCTGCCGAAGATTTGCCGGCAAATC-
TTCGGCAGCG-39. This, in turn, was ligated into the EcoRI
and HindIII sites of the cloning vector pGEM3zf(-) (Promega
Corporation, Madison, Wisconsin). An erythromycin resistance
cassette, ermB, was inserted upstream of the porA promoter within
the fragment upstream of nspA. N. meningitidis strain Z1092 was
Table 1. Description of genotype and phenotype of mutations used in this study.
Mutation Genotype Phenotype
mynB mynB::Cm results in unencapsulated derivative of group A meningococci
fHbp fHbp::Erm fHbp not expressed
lgtA lgtA::Kan results in LOS with lactose substitution on HepI (GalRGlcRHepI)
lgtF lgtF::Spc results in LOS without glycan extensions off HepI (HepI unsubstituted)
siaD siaD::Cm; interruption of the polysialyltransferase (siaD) in groups B, C, W-135 or Y
results in unencapsulated mutants
siaA siaA::Cm; blocks first enzyme in sia operon (GlcNAc-6-P epimerase); results in unencapsulated strains
that cannot synthesize CMP-NANA and therefore cannot endogenously sialylate its LNT LOS
lst lst::Kan interruption of the LOS sialyltransferase (lst) prevents LOS sialylation
nspA nspA::Spc No NspA expression
porB3 porB3::Erm No PorB3 expression
porA porA::Kan No PorA expression
nspA++ nspA under control of porA promoter; high-level NspA expression
nspAA2594comp pFP12 NspA A2594 (Tet
R) nspA under the control of it’s native promoter expressed from the low copy plasmid pFP12Tet
Cm, chloramphenicol; Erm, erythromycin; Kan, kanamycin; Spc, specctinomycin; Tet, tetracycline.
doi:10.1371/journal.ppat.1001027.t001
Neisserial NspA Binds Factor H
PLoS Pathogens | www.plospathogens.org 16 July 2010 | Volume 6 | Issue 7 | e1001027transformed by adding plasmid DNA in 10 mM MgCl2 to colonies
of Z1092 and incubating at 37uC enriched with 5% CO2 for
5 hours prior to plating onto chocolate agar with 5 mg/ml or
erythromycin. The level of NspA expression in erythromycin-
resistant colonies was analyzed by SDS-PAGE and Western
blotting using murine antisera raised against His-tagged-NspA. All
analyzed transformants expressed approximately 5-times the level
of NspA when compared with the wild-type strain (data not
shown). DNA extracted from Z1092 overexpressing NspA was
used to transform strain Y2220 and Y2220/L8 LOS; colonies
resistant to erythromycin were screened for increased NspA
production compared to the parent strain by Western blotting.
E. coli BL21 (DE3) pGMS 1.0 harboring a functional copy of
nspA and the preparation of microvesicles that contain NspA have
been described previously [40].
For simplicity, the capsule and LOS phenotype of each mutant
has been designated as follows: encapsulated strains, Cap+;
unencapsulated mutants, Cap2; sialylated lacto-N-neotetraose
LOS, LNT sia+; unsialylated lacto-N-neotetraose LOS, LNT;
LOS with lactose extension off HepI (lgtA mutants), L8 LOS and
LOS with no HepI saccharide extensions (lgtF mutants), HepI
unsubstituted.
Sera
Serum collected from a healthy human volunteer without a
history of meningococcal disease and who had not received any
meningococcal vaccines (normal human serum; NHS) was
aliquoted and stored at 280uC till used. Hemolytic activity of
the serum was confirmed using the Total Haemolytic Comple-
ment assay (Binding Site, Birmingham, U.K). Chimpanzee,
baboon and rhesus sera were purchased from Bioreclamation
(Bioreclamation, Hicksville, NY). Complement activity in the sera
was destroyed by heating at 56uC for 30 minutes. The serum used
did not contain any fHbp- or NspA-specific antibodies as revealed
by western blots of whole bacterial lysates that were probed with
serum.
Flow cytometry
Flow cytometry to detect bound fH was performed as described
previously [44]. Briefly, bacteria grown overnight on chocolate
agar plates were washed with Hanks Balanced Salt Solution
(HBSS) containing 1mM Ca
2+ and 1 mM Mg
2+ (HBSS
++) and
suspended to a final concentration of 3610
8 cells/ml; 10
8
organisms were centrifuged and incubated with fH purified from
human plasma (Complement Technology, Inc.; concentration
specified for each experiment). Bound fH was detected using either
affinity-isolated sheep anti-human fH (Lifespan Biosciences) or an
anti-fH mAb (Quidel, catalog no. A254 (mAb 906)), as available.
While the polyclonal antibody provided higher sensitivity, relative
differences in fH binding among strains using the two reagents
were similar. FITC conjugated anti-sheep IgG or anti-mouse IgG
(Sigma) were used as secondary antibodies. All reaction mixtures
were carried out in HBSS
++/1% BSA in a final volume of 50 ml.
Flow cytometry was performed using a FACSCalibur instrument
(Becton Dickinson) and data analysis was performed using the
FlowJo data analysis software package (www.TreeStar.com).
FH / murine Fc fusion constructs that contain contiguous fH
SCR domains (SCRs 1–5, 1–7, 6–10, 11–15, or 16–20) fused to
the N-terminus of the Fc fragment of murine IgG2a (fH/Fc fusion
proteins) have been described in detail previously [45]. To detect
binding of recombinant fH/Fc fusion proteins, bacteria were
incubated with concentrated tissue culture supernatant containing
0.5 mg of recombinant fH/Fc protein (as determined by ELISA) in
a final reaction volume of 100 ml for 30 min at 37uC. After
washing, FITC-labeled goat anti-mouse IgG (Sigma-Aldrich)
diluted 1:100 in 1% BSA/HBSS++ was used to detect bacteria-
bound fH/Fc fusion proteins.
Recombinant Factor H-like protein-1 (FHL-1) was generated as
previously described [44]. Following incubation of bacteria with
0.5 mg purified FHL-1, bound FHL-1 was detected using
monoclonal (mAb) 906 (specific for SCR1; detects both full-
length fH and FHL-1) and FITC-conjugated anti-mouse IgG
(Sigma) as previously described [44].
In some experiments, mAbs against NspA (mAb Me-7; IgG2a
[57] and 14C7 [40]) were used to block fH binding to intact
bacteria; mAb P1.9 against outer membrane protein PorA of strain
A2594 (National Institute of Biological Standards and Control) was
used as a control. Bacteria were incubated with tissue culture
supernatants containing mAbs Me-7 or P1.9 (the concentration of
mAb in supernatants was estimated by western blotting where serial
dilutions of the supernatants were compared against purified mouse
IgG standards of the same subclass) or purified mAb 14C7 for
15 min at 37uC followed by addition of purified fH. The reaction
mixture was incubated for an additional 15 min and bound fH was
detected using sheep anti-human fH as described above.
C3 deposition on bacteria that were incubated with normal
human serum (concentration specified for each experiment) was
measured using FITC-conjugated sheep anti-human C3 (Biode-
sign/Meridian Life Science, Inc.) as described previously [13].
Bacterial membrane preparations
Membranes were prepared from N. meningitidis strains A2594
and H44/76 and their fHbp deletion mutants as previously
described [13,70]. Briefly, bacteria harvested from five plates after
overnight culture on chocolate agar were suspended in normal
saline. Bacteria were washed, suspended in 5 ml of PBS containing
10 mM EDTA, and incubated at 60uC for 30 min. The bacterial
suspensions were sheared by sequential passage through progres-
sively smaller-gauge needles (18- through 25-gauge). The resultant
suspension was centrifuged at 50006g for 10 min at 4uCt o
separate any intact cells and debris. The supernatant was collected
and ultracentrifuged at 80,0006g for 90 min at 4uC to yield a
pellet that was enriched in outer membranes.
Western blotting
Far Western blotting was used to assess fH binding to membrane
preparations as described previously [13]. Membrane proteins were
separated on a 4–12% Bis-Tris gel (Invitrogen Life Technologies)
using MOPS running buffer. Proteins were transferred to
polyvinylidene difluoride membranes (Millipore) and blocked with
PBS-1% dry milk for 30 min at room temperature. Blocked
membranes were incubated overnight at 4uC with fH (1 mg/ml in
PBS-0.05% Tween 20). fH-binding proteins were detected using
affinity-isolated sheep anti-human fH (1 mg/ml in PBS-0.05%
Tween 20) anddisclosedusing anti-sheep IgG-alkalinephosphatase.
Western blotting was also used to assess NspA and fHbp
expression. To detect NspA, membranes were probed with tissue
culture supernatants that contained anti-NspA mAb Me-7
followed by anti-mouse IgG alkaline phosphatase. To detect fHbp
(variant 1, 2 and 3), membranes were probed with rabbit
polyclonal anti-serum that recognized variants 1, 2 and 3 fHbp
diluted 1:1000 in TBS 0.02% Tween 20 followed by anti-rabbit
IgG alkaline phosphatase. To ensure equal loading across lanes,
membranes were incised horizontally at the level of the ,40–
50 kD marker prior to the blocking step and stained with
Coomassie blue (Imperial Protein Stain kit, Pierce).
Binding of human, chimpanzee and rhesus macaque fH to
neisserial strains was measured by Western blotting as described
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8 bacteria were suspended in HBSS
2+
and incubated for 30 min at 37uC with 10% (v/v) heat-inactivated
NHS or heat-inactivated chimpanzee or rhesus serum in a final
reaction volume of 100 ml. Bacteria were washed three times in
HBSS
2+, the bacterial pellets were lysed with lithium dodecyl sulfate
sample buffer (Invitrogen, Carlsbad CA) and liberated fH was
detected after electrophoresis and transfer to PVDF using goat
polyclonal anti-human fH (Bethyl Laboratories, Montgomery, TX)
that also recognizes chimpanzee and rhesus fH [45], followed by
alkaline phosphatase-conjugated anti-goat IgG (Sigma). Human
and the non-human primate sera alone served as positive controls.
MALDI-TOF analysis
Outer membrane proteins were separated by electrophoresis as
described above and stained with colloidal Coomassie brilliant
blue (Sigma-Aldrich). The band corresponding to the ,17 kDa
band that bound fH was excised, washed extensively and then
digested ‘‘in gel’’ with trypsin as described elsewhere [71].
Digested peptides were further purified via micro Zip Tipping.
Briefly, samples dried down to a 10 ml volume were acidified with
1–2 ml of 1% TFA and then loaded on a Zip Tipm-C18 (Millipore,
Corp) that had been pre-equilibrated with 0.1% TFA. After
washing with twice with 10 ml aliquots of 0.1%, TFA samples were
deposited directly onto the MALDI sample target using 1 mlo f
Matrix solution (15 mg/ml of 2,5-dihydroxybenzoic Acid (Mas-
sPrep DHB, Waters Corp.) in 50:50 acetonitrile: 0.1% TFA).
Samples were allowed to air dry prior to insertion into the mass
spectrometer. Analysis was performed on a Kratos Axima QIT
(Shimadzu Instruments) matrix-assisted-laser desorption/ioniza-
tion (MALDI) mass spectrometer. Peptides were analyzed in
positive ion mode in mid-mass range (700–3000 Da). The
instrument was externally calibrated with Angiotensin II
(1046.54 Da), P14R (1533.86 Da) and ACTH (18–39)
(2465.20 Da). Precursors were selected based on signal intensity
at a mass resolution width of 250 for CID fragmentation using
Argon as the collision gas. Database searches were performed in
house with Mascot (Matrix Sciences, Ltd.) using the Peptide Mass
Fingerprint program for MS data and the MS/MS Ion Search
program for CID data. All identifications were confirmed or
established with CID (MS/MS) data.
Serum bactericidal assays
Susceptibility of meningococci to complement mediated killing
was determined using a serum bactericidal assay as described
previously [44,72]. The optimal concentration of serum was
determined empirically for each strain (Supplementary Figure S5).
Bacteria from an overnight culture on chocolate agar plates were
inoculated onto fresh chocolate agar and allowed to grow for ,6h
at 37uCi n5 %C O 2. Normal human serum was obtained from a
healthy human volunteer and stored at 270uC till used in
bactericidal assays. Briefly, 2000 CFUs of meningococci were
incubatedwith serum(concentrationsspecified foreachexperiment)
in a final reaction volume of 150 ml. Aliquots of 25 ml were plated in
duplicate at the start of the assay (t0) and after incubating the
reaction mixture at 37uC for 30 min (t30). Survival was calculated as
the number of viable colonies at t30 relative to baseline colony
counts at t0. Each experiment was repeated at least three times.
ELISA to detect binding of fH to microvesicles containing
NspA
E. coli BL21(DE3) (Invitrogen, Carlsbad, CA) harboring
recombinant NspA on plasmid pGMS 1.0 and E. coli BL21(DE3)
transformed with pBluescript II SK+ (Stratagene, La Jolla, CA)
were used to prepare microvesicles as previously described [40].
An ELISA was used to detect fH binding to NspA containing
vesicles. Microtiter wells were coated with either NspA-producing
vesicles or with control vesicles each at a concentration of 10 mg/
ml in PBS overnight at 22uC. Nonspecific biding sites were
blocked with PBS/2.5% BSA for 2 h at 37uC. To demonstrate the
ability of anti-NspA mAb 14C7 to block fH binding to NspA-
containing vesicles, select wells were incubated with mAb 14C7
(10 mg/ml) in PBS/0.05% Tween 20 for 1 h at 37uC; the
remaining wells were incubated with PBS/Tween alone. fH
(concentrations ranging from 0 to 10 mg/ml) was then added to
wells for 1 h at 37uC, and bound fH was detected using polyclonal
sheep anti-human fH followed by anti-sheep IgG conjugated with
alkaline phosphatase, each for 1 h at 37uC.
Statistical methods
Cuzick’s nonparametric test for trend across ordered groups
[73] was used to determine if there was a trend between the
binding of fH and the length of glycan extensions from the HepI
chain of LOS. Median fluorescence values from three independent
experiments were used in the analysis. Strains expressing LNT
LOS, L8 LOS and unsubstituted LOS were ordered decreasingly
by the length of the HepI glycans extensions and scored as 5, 3 and
1, respectively. The measurement of binding was divided by the
value of the control for normalizing. The analysis was done
separately for strains A2594 Cap+ and A2594 Cap2. The results
showed a statistically significant trend between fH binding and
decreasing length of HepI glycan extensions for both Cap+ and
Cap2 strains (Table S2; results are the same for A2594 Cap+ and
A2594 Cap2, p=0.007).
For bactericidal assays the average survival was calculated from
at least three independent experiments and error bars represent
the standard deviation. A t-test was used to determine significance.
Supporting Information
Figure S1 Neisserial Opa proteins are not involved in binding of
fH to N. meningitidis. fH binding to Opa+ unencapsulated
meningococcal strain Z2087 (solid black line) and its unencapsu-
lated isogenic Opa negative mutant (shaded grey) was examined
by flow cytometry. Bacteria were incubated with purified human
fH at a concentration of 20 mg/ml and bound fH was detected
with polyclonal sheep anti-human fH. Representative controls
with the parent strain where fH was omitted from the reaction
mixture is shown by the broken line. The x-axis represents
fluorescence on a log10 scale and the y axis is the number of events.
Found at: doi:10.1371/journal.ppat.1001027.s001 (0.13 MB TIF)
Figure S2 Expression of fHbp and NspA in BZ198, A2594 and
Z2087 derivatives as determined by Western blotting of whole cell
lysates followed by detection with polyclonal anti-fHbp (variant 1,2
and 3) or anti-NspA mAb Me-7 as indicated. Strains with altered
capsule (cap+ or cap2) and LOS structures were examines. The
HepI of LOS was substituted with either lacto-N-neotetraose
(LNT), lactose (L8) or was unsubstituted (U). Growth in the
presence of CMP-NANA to sialylate LNT LOS is as indicated.
After transfer, proteins migrating above ,50 kD were stained with
Coomassie blue and served as a loading control, proteins
migrating between ,20 kD and 40 kD were probed to detect
fHbp and proteins migrating below 20 kD were probed to detect
NspA. NspA migrates with an apparent molecular mass of
approximately 15 kD when 4–12% Bis-Tris gels are used with
MES running buffer. Of note, NspA is a heat-modifiable protein
and the second larger anti-NspA-reactive band seen in some lanes
is the result of incomplete heat denaturation.
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Figure S3 Truncating the HepI chain of LOS in low and
intermediate NspA expressing strains discloses fH binding. fH
(10 mg/ml) binding to the Cap2/LNT sia2 mutants of strains
H44/76, C2120, W171 and Y2220 were compared to their
isogenic mutants that lacked glycan extensions from HepI (HepI
unsubstituted).
Found at: doi:10.1371/journal.ppat.1001027.s003 (0.28 MB TIF)
Figure S4 Binding of purified recombinant FHL-1 (7mg/ml) to
encapsulated (gray shaded histogram) and unencapsulated (solid
black line) N. meningitidis strain A2594 that expresses NspA but not
fHbp. In all graphs, the x-axis represents fluorescence on a log10
scale and the y-axis the number of events. Numbers represent the
median fluorescence of the corresponding histogram. Purified
FHL-1 was omitted from control reaction mixtures (broken line).
Found at: doi:10.1371/journal.ppat.1001027.s004 (0.11 MB TIF)
Figure S5 Titration of serum concentrations to determine the
level of serum resistance of BZ198 Cap+ L8 LOS and A2594
Cap2 L8 LOS. Strains BZ198 Cap+ L8 LOS (left graph) and
A2594 Cap2 L8 LOS (right graph) were tested for their ability to
resist killing by normal human serum in a serum bactericidal assay.
The y-axis represents percent survival and the x-axis represents the
percent serum used in the assay. Error bars indicate standard
deviation calculated from 3 independent experiments.
Found at: doi:10.1371/journal.ppat.1001027.s005 (0.15 MB TIF)
Table S1 Estimated mean of normalized fH binding and p-
values for trend test.
Found at: doi:10.1371/journal.ppat.1001027.s006 (0.05 MB
DOC)
Table S2 Meningococcal strains used in this study and their
relevant characteristics.
Found at: doi:10.1371/journal.ppat.1001027.s007 (0.15 MB
DOC)
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